Patient & Visitor Alert: Because flu cases are on the rise, starting February 24, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities throughout Carolinas HealthCare System. Learn more.
This study will compare the results of transarterial chemoembolization (TACE) and microwave ablation (MWA) combination therapy with MWA monotherapy for the treatment of early (stages O and A) hepatocellular carcinoma (HCC). The primary aim is to compare 2-year intrahepatic disease-free survival. Secondary aims are: 1) to determine the clinical feasibility of TACE + MWA in HCC patients with a small burden, and 2) to determine the effect of TACE on radiographic tumor characteristics.
Who may be Eligible
Male or female patients aged 18 to 75 years with a primary diagnosis of hepatocellular carcinoma.